Table 1 Characteristics of populations and cancer types of the studies included in the meta-analysis
Study | Country | Ethnicity | Cancer type | Sample size case/control | Source of controls | Genotyping method | Polymorphisms |
|---|---|---|---|---|---|---|---|
Misra 2003 20 | Finland | European | Lung cancer | 310/302 | Population | TaqMan | 1349 T > G |
Popanda 2004 21 | Germany | European | Lung cancer | 459/457 | Hospital | Rapid capillary PCR | 1349 T > G |
Hao 2004 22 | China | Asian | Oesophageal cancer | 409/478 | Population | PCR-RFLP | 1349 T > G |
Ito 2004 23 | Japan | Asian | Lung cancer | 178/449 | Hospital | PCR-RFLP | 1349 T > G |
Shen 2005 24 | China | Asian | Lung cancer | 117/113 | Population | TaqMan | 1349 T > G |
Moreno 2006 25 | Spain | European | Colorectal cancer | 359/312 | Hospital | Arrayed primer extension | 1349 T > G |
Jiao 2006 26 | USA | European | Pancreatic cancer | 367/330 | Hospital | Allele-specific PCR | 1349 T > G |
Terry 2006 27 | USA | European | Bladder cancer | 229/207 | Hospital | MALDI-TOF | 1349 T > G |
Wu 2006 28 | USA | European | Bladder cancer | 596/590 | Hospital | TaqMan | 1349 T > G |
Zhang 2006 29 | USA | European | Breast cancer | 1529/1207 | Population | TaqMan | 1349 T > G |
Matullo 2006 30 | Multi-country | European | Breast cancer | 124/1094 | Population | TaqMan | 1349 T > G |
Lung cancer | 116/1094 | Population | TaqMan | 1349 T > G | |||
Head and neck cancer | 82/1094 | Population | TaqMan | 1349 T > G | |||
Leukemia | 169/1094 | Population | TaqMan | 1349 T > G | |||
Chen 2006 31 | USA | Mixed | Prostate cancer | 351/329 | Hospital | PCR-RFLP | 1349 T > G |
Li 2007 32 | USA | European | Head and neck cancer | 830/854 | Hospital | PCR-RFLP | 1349 T > G |
Berndt 2007 14 | USA | European | Colorectal cancer | 767/773 | Population | TaqMan | 1349 T > G, −656 T > G |
Figueroa 2007 15 | Spain | European | Bladder cancer | 1150/1149 | Hospital | TaqMan | 1349 T > G, −656 T > G |
Andrew 2008 33 | USA/Italy | European | Bladder cancer | 911/1165 | Population | SNP mass-tagging system | 1349 T > G |
Pardini 2008 34 | Czech | European | Colorectal cancer | 531/530 | Hospital | TaqMan | 1349 T > G |
Mitra 2008 35 | India | European | Bladder cancer | 150/225 | Population | PCR-RFLP | 1349 T > G |
Tse 2008 36 | USA | European | Colorectal cancer | 311/454 | Hospital | TaqMan | 1349 T > G |
Huang 2008 37 | China | Asian | Biliary tract cancer | 409/783 | Population | TaqMan | 1349 T > G |
Chiang 2008 38 | China | Asian | Thyroid cancer | 283/469 | Hospital | TaqMan | 1349 T > G |
Smith 2008 39 | USA | Asian | Breast cancer | 372/480 | Hospital | Arrayed primer extension | 1349 T > G |
Gangwar 2009 40 | India | European | Bladder cancer | 206/250 | Hospital | TaqMan | 1349 T > G |
Agachan 2009 41 | Turkey | European | Lung cancer | 98/67 | Hospital | PCR-RFLP | 1349 T > G |
Lo 2009 11 | China | Asian | Lung cancer | 729/722 | Hospital | Arrayed primer extension | 1349 T > G, −656 T > G |
Lu 2009 10 | China | Asian | Lung cancer | 500/517 | Population | Illumina | 1349 T > G, −656 T > G |
Lung cancer | 572/547 | Hospital | SNPscan | −656 T > G | |||
Wang 2010 12 | China | Asian | Bladder cancer | 234/253 | Hospital | PCR-RFLP | 1349 T > G, -656 T > G |
Deng 2010 42 | China | Asian | Lung cancer | 315/314 | Population | RT-PCR | 1349 T > G |
Palli 2010 43 | Italy | European | Gastric cancer | 298/546 | Population | TaqMan | 1349 T > G |
Jelonek 2010 44 | Poland | European | Colorectal cancer | 113/153 | Hospital | PCR-RFLP | 1349 T > G |
Breast cancer | 91/412 | Hospital | PCR-RFLP | 1349 T > G | |||
Zhou 2011 13 | China | Asian | Brain cancer | 750/816 | Hospital | MassARRAY | −656 T > G |
Cao 2011 45 | China | Asian | Renal cell carcinoma | 612/632 | Hospital | TaqMan | 1349 T > G, -656 T > G |